> top > docs > PubMed:12076385 > annotations

PubMed:12076385 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-PubTator-for-Tuning

Id Subject Object Predicate Lexical cue tao:has_database_id
1 90-110 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
21 191-203 ChemicalEntity denotes prednisolone MESH:D011239
22 222-230 OrganismTaxon denotes patients Tax:9606
23 236-256 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
24 583-595 ChemicalEntity denotes prednisolone MESH:D011239
25 671-679 OrganismTaxon denotes patients Tax:9606
26 685-705 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
27 1079-1091 ChemicalEntity denotes prednisolone MESH:D011239
28 1587-1595 OrganismTaxon denotes patients Tax:9606
29 1633-1645 ChemicalEntity denotes Prednisolone MESH:D011239
30 1682-1698 DiseaseOrPhenotypicFeature denotes joint tenderness
31 1770-1774 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
32 2008-2020 ChemicalEntity denotes Prednisolone MESH:D011239
33 2093-2109 DiseaseOrPhenotypicFeature denotes joint tenderness
34 2160-2164 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
35 2537-2549 ChemicalEntity denotes Prednisolone MESH:D011239
36 2621-2629 OrganismTaxon denotes patients Tax:9606
37 2635-2655 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
38 2728-2740 ChemicalEntity denotes prednisolone MESH:D011239
39 2840-2852 ChemicalEntity denotes prednisolone MESH:D011239

LitCoin-Disease-Tuning-1

Id Subject Object Predicate Lexical cue ID:
T1 90-110 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T2 236-256 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T3 398-410 DiseaseOrPhenotypicFeature denotes inflammatory DISEASE
T4 685-705 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T5 1770-1774 DiseaseOrPhenotypicFeature denotes pain D010146
T6 2160-2164 DiseaseOrPhenotypicFeature denotes pain D010146
T7 2635-2655 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T8 2677-2684 DiseaseOrPhenotypicFeature denotes disease D004194

LitEisuke

Id Subject Object Predicate Lexical cue #label
T1 90-110 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T2 236-256 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T3 685-705 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T4 1770-1774 DiseaseOrPhenotypicFeature denotes pain D010146
T5 2160-2164 DiseaseOrPhenotypicFeature denotes pain D010146
T6 2635-2655 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-111 Sentence denotes Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
T2 112-123 Sentence denotes BACKGROUND:
T3 124-277 Sentence denotes The effectiveness of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned.
T4 278-417 Sentence denotes We therefore performed a systematic review of trials which compared corticosteroids with placebo or non-steroidal, anti-inflammatory drugs.
T5 418-429 Sentence denotes OBJECTIVES:
T6 430-706 Sentence denotes To determine whether short-term (i.e. as recorded within the first month of therapy), oral low-dose corticosteroids (corresponding to a maximum of 15 mg prednisolone daily) is superior to placebo and non steroidal, antiinflammatory drugs in patients with rheumatoid arthritis.
T7 707-723 Sentence denotes SEARCH STRATEGY:
T8 724-827 Sentence denotes Medline Silverplatter, The Cochrane Controlled Trials Register, reference lists and a personal archive.
T9 828-857 Sentence denotes Date of last search Nov 2001.
T10 858-877 Sentence denotes SELECTION CRITERIA:
T11 878-984 Sentence denotes This review is an update to a previous review which was peer-review and published in the Cochrane Library.
T12 985-1243 Sentence denotes All randomised studies comparing an oral corticosteroid (not exceeding an equivalent of 15 mg prednisolone daily) with placebo or a non steroidal, antiinflammatory drug were eligible if they reported clinical outcomes within one month after start of therapy.
T13 1244-1273 Sentence denotes DATA COLLECTION AND ANALYSIS:
T14 1274-1401 Sentence denotes Decisions on which trials to include were made independently by two observers based on the methods sections of the trials only.
T15 1402-1545 Sentence denotes Standardised effect measures were used for the statistical analyses; the random effects model was used if P<0.10 for the test of heterogeneity.
T16 1546-1559 Sentence denotes MAIN RESULTS:
T17 1560-1632 Sentence denotes Ten studies, involving 320 patients, were included in the meta-analysis.
T18 1633-1885 Sentence denotes Prednisolone had a marked effect over placebo on joint tenderness (standardised effect size 1.31, 95% confidence interval 0.78 to 1.83), pain (standardised effect size 1.75, 0.87 to 2.64) and grip strength (standardised effect size 0.41, 0.13 to 0.69).
T19 1886-2007 Sentence denotes Measured in the original units, the differences were 12 tender joints (6 to 18) and 22 mm Hg (5 to 40) for grip strength.
T20 2008-2319 Sentence denotes Prednisolone also had a greater effect than non steroidal, antiinflammatory drugs on joint tenderness (standardised effect size 0.63, 0.11 to 1.16) and pain (standardised effect size 1.25, 0.26 to 2.24), whereas the difference in grip strength was not significant (standardised effect size 0.31, -0.02 to 0.64).
T21 2320-2423 Sentence denotes Measured in the original units, the differences were 9 tender joints (5 to 12) and 12 mm Hg (-6 to 31).
T22 2424-2512 Sentence denotes The risk of adverse effects, also during moderate- and long-term use, seemed acceptable.
T23 2513-2536 Sentence denotes REVIEWER'S CONCLUSIONS:
T24 2537-2721 Sentence denotes Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.
T25 2722-2907 Sentence denotes Since prednisolone is highly effective, short-term placebo controlled trials studying the clinical effect of low-dose prednisolone or other oral corticosteroids are no longer necessary.
T1 0-111 Sentence denotes Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
T2 112-123 Sentence denotes BACKGROUND:
T3 124-277 Sentence denotes The effectiveness of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned.
T4 278-417 Sentence denotes We therefore performed a systematic review of trials which compared corticosteroids with placebo or non-steroidal, anti-inflammatory drugs.
T5 418-429 Sentence denotes OBJECTIVES:
T6 430-706 Sentence denotes To determine whether short-term (i.e. as recorded within the first month of therapy), oral low-dose corticosteroids (corresponding to a maximum of 15 mg prednisolone daily) is superior to placebo and non steroidal, antiinflammatory drugs in patients with rheumatoid arthritis.
T7 707-723 Sentence denotes SEARCH STRATEGY:
T8 724-827 Sentence denotes Medline Silverplatter, The Cochrane Controlled Trials Register, reference lists and a personal archive.
T9 828-857 Sentence denotes Date of last search Nov 2001.
T10 858-877 Sentence denotes SELECTION CRITERIA:
T11 878-984 Sentence denotes This review is an update to a previous review which was peer-review and published in the Cochrane Library.
T12 985-1243 Sentence denotes All randomised studies comparing an oral corticosteroid (not exceeding an equivalent of 15 mg prednisolone daily) with placebo or a non steroidal, antiinflammatory drug were eligible if they reported clinical outcomes within one month after start of therapy.
T13 1244-1273 Sentence denotes DATA COLLECTION AND ANALYSIS:
T14 1274-1401 Sentence denotes Decisions on which trials to include were made independently by two observers based on the methods sections of the trials only.
T15 1402-1545 Sentence denotes Standardised effect measures were used for the statistical analyses; the random effects model was used if P<0.10 for the test of heterogeneity.
T16 1546-1559 Sentence denotes MAIN RESULTS:
T17 1560-1632 Sentence denotes Ten studies, involving 320 patients, were included in the meta-analysis.
T18 1633-1885 Sentence denotes Prednisolone had a marked effect over placebo on joint tenderness (standardised effect size 1.31, 95% confidence interval 0.78 to 1.83), pain (standardised effect size 1.75, 0.87 to 2.64) and grip strength (standardised effect size 0.41, 0.13 to 0.69).
T19 1886-2007 Sentence denotes Measured in the original units, the differences were 12 tender joints (6 to 18) and 22 mm Hg (5 to 40) for grip strength.
T20 2008-2319 Sentence denotes Prednisolone also had a greater effect than non steroidal, antiinflammatory drugs on joint tenderness (standardised effect size 0.63, 0.11 to 1.16) and pain (standardised effect size 1.25, 0.26 to 2.24), whereas the difference in grip strength was not significant (standardised effect size 0.31, -0.02 to 0.64).
T21 2320-2423 Sentence denotes Measured in the original units, the differences were 9 tender joints (5 to 12) and 12 mm Hg (-6 to 31).
T22 2424-2512 Sentence denotes The risk of adverse effects, also during moderate- and long-term use, seemed acceptable.
T23 2513-2536 Sentence denotes REVIEWER'S CONCLUSIONS:
T24 2537-2721 Sentence denotes Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.
T25 2722-2907 Sentence denotes Since prednisolone is highly effective, short-term placebo controlled trials studying the clinical effect of low-dose prednisolone or other oral corticosteroids are no longer necessary.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 236-256 HP_0001370 denotes rheumatoid arthritis
T2 247-256 HP_0001369 denotes arthritis